3k0h › Citations

Comparison of the structures and peptide binding specificities of the BRCT domains of MDC1 and BRCA1.

Campbell SJ, Edwards RA, Glover JN
Structure 18 167-76 (2010)
Related entries: 3k05, 3k0k, 3k15, 3k16

Cited: 39 times
EuropePMC logo PMID: 20159462

Abstract

The tandem BRCT domains of BRCA1 and MDC1 facilitate protein signaling at DNA damage foci through specific interactions with serine-phosphorylated protein partners. The MDC1 BRCT binds pSer-Gln-Glu-Tyr-COO(-) at the C terminus of the histone variant gammaH2AX via direct recognition of the C-terminal carboxylate, while BRCA1 recognizes pSer-X-X-Phe motifs either at C-terminal or internal sites within target proteins. Using fluorescence polarization binding assays, we show that while both BRCTs prefer a free main chain carboxylate at the +3 position, this preference is much more pronounced in MDC1. Crystal structures of BRCA1 and MDC1 bound to tetrapeptide substrates reveal differences in the environment of conserved arginines (Arg1699 in BRCA1 and Arg1933 in MDC1) that determine the relative affinity for peptides with -COO(-) versus -CO-NH(2) termini. A mutation in MDC1 that induces a more BRCA1-like conformation relaxes the binding specificity, allowing the mutant to bind phosphopeptides lacking a -COO(-) terminus.

Reviews - 3k0h mentioned but not cited (2)

  1. Phosphopeptide interactions with BRCA1 BRCT domains: More than just a motif. Wu Q, Jubb H, Blundell TL. Prog. Biophys. Mol. Biol. 117 143-148 (2015)
  2. Fanconi anemia pathway as a prospective target for cancer intervention. Liu W, Palovcak A, Li F, Zafar A, Yuan F, Zhang Y. Cell Biosci 10 39 (2020)

Articles - 3k0h mentioned but not cited (6)

  1. Structure-Function Of The Tumor Suppressor BRCA1. Clark SL, Rodriguez AM, Snyder RR, Hankins GD, Boehning D. Comput Struct Biotechnol J 1 (2012)
  2. Acetylation of lysine 382 and phosphorylation of serine 392 in p53 modulate the interaction between p53 and MDC1 in vitro. Shahar OD, Gabizon R, Feine O, Alhadeff R, Ganoth A, Argaman L, Shimshoni E, Friedler A, Goldberg M. PLoS ONE 8 e78472 (2013)
  3. A microchip platform for structural oncology applications. Winton CE, Gilmore BL, Demmert AC, Karageorge V, Sheng Z, Kelly DF. NPJ Breast Cancer 2 (2016)
  4. Molecular Analysis of BRCA1 in Human Breast Cancer Cells Under Oxidative Stress. Gilmore BL, Liang Y, Winton CE, Patel K, Karageorge V, Varano AC, Dearnaley W, Sheng Z, Kelly DF. Sci Rep 7 43435 (2017)
  5. A computational approach to the study of interactions between proteins and miR10-b, miR-335, and miR-21 involved in breast cancer. Hammou RA, Kasmi Y, Ennaji MM. Contemp Oncol (Pozn) 23 220-225 (2019)
  6. Dexibuprofen amide derivatives as potential anticancer agents: synthesis, in silico docking, bioevaluation, and molecular dynamic simulation. Ashraf Z, Mahmood T, Hassan M, Afzal S, Rafique H, Afzal K, Latip J. Drug Des Devel Ther 13 1643-1657 (2019)


Reviews citing this publication (6)

  1. BRCT domains: easy as one, two, three. Leung CC, Glover JN. Cell Cycle 10 2461-2470 (2011)
  2. The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Paul A, Paul S. Front Biosci (Landmark Ed) 19 605-618 (2014)
  3. Structural mechanisms underlying signaling in the cellular response to DNA double strand breaks. Mermershtain I, Glover JN. Mutat. Res. 750 15-22 (2013)
  4. Reading chromatin signatures after DNA double-strand breaks. Wilson MD, Durocher D. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 372 (2017)
  5. Phosphorylation-dependent assembly of DNA damage response systems and the central roles of TOPBP1. Day M, Oliver AW, Pearl LH. DNA Repair (Amst) 108 103232 (2021)
  6. Tutorial: a guide for the selection of fast and accurate computational tools for the prediction of intrinsic disorder in proteins. Kurgan L, Hu G, Wang K, Ghadermarzi S, Zhao B, Malhis N, Erdős G, Gsponer J, Uversky VN, Dosztányi Z. Nat Protoc 18 3157-3172 (2023)

Articles citing this publication (25)

  1. The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response. Li M, Lu LY, Yang CY, Wang S, Yu X. Genes Dev. 27 1752-1768 (2013)
  2. Chemical proteomics reveals a γH2AX-53BP1 interaction in the DNA damage response. Kleiner RE, Verma P, Molloy KR, Chait BT, Kapoor TM. Nat. Chem. Biol. 11 807-814 (2015)
  3. Dual recognition of phosphoserine and phosphotyrosine in histone variant H2A.X by DNA damage response protein MCPH1. Singh N, Basnet H, Wiltshire TD, Mohammad DH, Thompson JR, Héroux A, Botuyan MV, Yaffe MB, Couch FJ, Rosenfeld MG, Mer G. Proc. Natl. Acad. Sci. U.S.A. 109 14381-14386 (2012)
  4. Molecular basis of BACH1/FANCJ recognition by TopBP1 in DNA replication checkpoint control. Leung CC, Gong Z, Chen J, Glover JN. J. Biol. Chem. 286 4292-4301 (2011)
  5. Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition. Coquelle N, Green R, Glover JN. Biochemistry 50 4579-4589 (2011)
  6. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Pessetto ZY, Yan Y, Bessho T, Natarajan A. Breast Cancer Res. Treat. 134 511-517 (2012)
  7. Structure of BRCA1-BRCT/Abraxas Complex Reveals Phosphorylation-Dependent BRCT Dimerization at DNA Damage Sites. Wu Q, Paul A, Su D, Mehmood S, Foo TK, Ochi T, Bunting EL, Xia B, Robinson CV, Wang B, Blundell TL. Mol. Cell 61 434-448 (2016)
  8. Exploiting the P-1 pocket of BRCT domains toward a structure guided inhibitor design. Yuan Z, Kumar EA, Campbell SJ, Palermo NY, Kizhake S, Mark Glover JN, Natarajan A. ACS Med Chem Lett 2 764-767 (2011)
  9. Molecular adaptation of telomere associated genes in mammals. Morgan CC, Mc Cartney AM, Donoghue MT, Loughran NB, Spillane C, Teeling EC, O'Connell MJ. BMC Evol. Biol. 13 251 (2013)
  10. Saccharomyces cerevisiae Dbf4 has unique fold necessary for interaction with Rad53 kinase. Matthews LA, Jones DR, Prasad AA, Duncker BP, Guarné A. J. Biol. Chem. 287 2378-2387 (2012)
  11. Structure-activity relationship studies to probe the phosphoprotein binding site on the carboxy terminal domains of the breast cancer susceptibility gene 1. Yuan Z, Kumar EA, Kizhake S, Natarajan A. J. Med. Chem. 54 4264-4268 (2011)
  12. Discovery of cell-permeable inhibitors that target the BRCT domain of BRCA1 protein by using a small-molecule microarray. Na Z, Pan S, Uttamchandani M, Yao SQ. Angew. Chem. Int. Ed. Engl. 53 8421-8426 (2014)
  13. Molecular basis for the association of microcephalin (MCPH1) protein with the cell division cycle protein 27 (Cdc27) subunit of the anaphase-promoting complex. Singh N, Wiltshire TD, Thompson JR, Mer G, Couch FJ. J. Biol. Chem. 287 2854-2862 (2012)
  14. Computational and experimental studies of the interaction between phospho-peptides and the C-terminal domain of BRCA1. Anisimov VM, Ziemys A, Kizhake S, Yuan Z, Natarajan A, Cavasotto CN. J. Comput. Aided Mol. Des. 25 1071-1084 (2011)
  15. "DNA Binding Region" of BRCA1 Affects Genetic Stability through modulating the Intra-S-Phase Checkpoint. Masuda T, Xu X, Dimitriadis EK, Lahusen T, Deng CX. Int. J. Biol. Sci. 12 133-143 (2016)
  16. Crystal structure of triple-BRCT-domain of ECT2 and insights into the binding characteristics to CYK-4. Zou Y, Shao Z, Peng J, Li F, Gong D, Wang C, Zuo X, Zhang Z, Wu J, Shi Y, Gong Q. FEBS Lett. 588 2911-2920 (2014)
  17. Specific recognition of phosphorylated tail of H2AX by the tandem BRCT domains of MCPH1 revealed by complex structure. Shao Z, Li F, Sy SM, Yan W, Zhang Z, Gong D, Wen B, Huen MS, Gong Q, Wu J, Shi Y. J. Struct. Biol. 177 459-468 (2012)
  18. Clinically Significant Unclassified Variants in BRCA1 and BRCA2 genes among Korean Breast Cancer Patients. Yoon KA, Park B, Lee BI, Yang MJ, Kong SY, Lee ES. Cancer Res Treat 49 627-634 (2017)
  19. Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain. White ER, Sun L, Ma Z, Beckta JM, Danzig BA, Hacker DE, Huie M, Williams DC, Edwards RA, Valerie K, Glover JN, Hartman MC. ACS Chem. Biol. 10 1198-1208 (2015)
  20. Achieving peptide binding specificity and promiscuity by loops: case of the forkhead-associated domain. Huang YM, Chang CE. PLoS ONE 9 e98291 (2014)
  21. Targeting Phosphopeptide Recognition by the Human BRCA1 Tandem BRCT Domain to Interrupt BRCA1-Dependent Signaling. Periasamy J, Kurdekar V, Jasti S, Nijaguna MB, Boggaram S, Hurakadli MA, Raina D, Kurup LM, Chintha C, Manjunath K, Goyal A, Sadasivam G, Bharatham K, Padigaru M, Potluri V, Venkitaraman AR. Cell Chem Biol 25 677-690.e12 (2018)
  22. β-Hairpins as peptidomimetics of human phosphoprotein-binding domains. Batalha IL, Lychko I, Branco RJF, Iranzo O, Roque ACA. Org Biomol Chem 17 3996-4004 (2019)
  23. ADAD2 regulates heterochromatin in meiotic and post-meiotic male germ cells via translation of MDC1. Chukrallah LG, Badrinath A, Vittor GG, Snyder EM. J Cell Sci 135 jcs259196 (2022)
  24. ID3 regulates the MDC1-mediated DNA damage response in order to maintain genome stability. Lee JH, Park SJ, Hariharasudhan G, Kim MJ, Jung SM, Jeong SY, Chang IY, Kim C, Kim E, Yu J, Bae S, You HJ. Nat Commun 8 903 (2017)
  25. Synthesis of unnatural amino acid derivatives via palladium catalyzed 1,4 addition of boronic acids. Ray D, Nyong AM, Natarajan A. Tetrahedron Lett. 51 2655-2656 (2010)


Quick links